Gene Therapy for Pain: Results of a Phase I Clinical Trial

Overview

Journal Ann Neurol

Specialty Neurology

Date 2011 Jul 29

PMID 21796661

Citations 77

Authors

David J Fink

James Wechuck

Marina Mata

Joseph C Glorioso

James Goss

David Krisky

Darren Wolfe

Affiliations

Soon will be listed here.

Abstract

Objective: Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication-defective herpes simplex virus (HSV)-based vectors can reduce pain-related behavior in animal models of pain. This clinical trial was carried out to assess the safety and explore the potential efficacy of this approach in humans.

Methods: We conducted a multicenter, dose-escalation, phase I clinical trial of NP2, a replication-defective HSV-based vector expressing human preproenkephalin (PENK) in subjects with intractable focal pain caused by cancer. NP2 was injected intradermally into the dermatome(s) corresponding to the radicular distribution of pain. The primary outcome was safety. As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (NRS), the Short Form McGill Pain Questionnaire (SF-MPQ), and concurrent opiate usage.

Results: Ten subjects with moderate to severe intractable pain despite treatment with >200mg/day of morphine (or equivalent) were enrolled into the study. Treatment was well tolerated with no study agent-related serious adverse events observed at any point in the study. Subjects receiving the low dose of NP2 reported no substantive change in pain. Subjects in the middle- and high-dose cohorts reported pain relief as assessed by NRS and SF-MPQ.

Interpretation: Treatment of intractable pain with NP2 was well tolerated. There were no placebo controls in this relatively small study, but the dose-responsive analgesic effects suggest that NP2 may be effective in reducing pain and warrants further clinical investigation.

Citing Articles

Neurosurgical Interventions in Chronic Pain Management: A Review of Emerging Technologies and Accessibility.

Woehl L, Pereira E Curr Pain Headache Rep. 2025; 29(1):58.

PMID: 40063194 DOI: 10.1007/s11916-025-01374-3.

Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update.

Le Hars M, Joussain C, Jegu T, Epstein A Gene Ther. 2024; .

PMID: 39533042 DOI: 10.1038/s41434-024-00500-x.

Gene therapy for chronic pain management.

Li Y, Ji R Cell Rep Med. 2024; 5(10):101756.

PMID: 39366385 PMC: 11513853. DOI: 10.1016/j.xcrm.2024.101756.

Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome.

Hu J, Tzeng H, Lee W, Li J, Chuang Y Int J Mol Sci. 2024; 25(15).

PMID: 39125584 PMC: 11312208. DOI: 10.3390/ijms25158015.

Safety of non-replicative and oncolytic replication-selective HSV vectors.

Epstein A, Rabkin S Trends Mol Med. 2024; 30(8):781-794.

PMID: 38886138 PMC: 11329358. DOI: 10.1016/j.molmed.2024.05.014.

References

Caterina M . On the thermoregulatory perils of TRPV1 antagonism. Pain. 2008; 136(1-2):3-4. DOI: 10.1016/j.pain.2008.02.033. View

Hao S, Mata M, Wolfe D, Huang S, Glorioso J, Fink D . Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol. 2005; 57(6):914-8. PMC: 1242042. DOI: 10.1002/ana.20483. View

Chattopadhyay M, Mata M, Goss J, Wolfe D, Huang S, Glorioso J . Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia. 2007; 50(7):1550-8. DOI: 10.1007/s00125-007-0702-4. View

Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M . Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain. 2007; 133(1-3):29-38. DOI: 10.1016/j.pain.2007.02.003. View

Storek B, Reinhardt M, Wang C, Janssen W, Harder N, Banck M . Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A. 2008; 105(3):1055-60. PMC: 2242718. DOI: 10.1073/pnas.0708003105. View

Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P . Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008; 11(3):492-501. DOI: 10.1089/jpm.2007.0200. View

Woolf C . Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2010; 152(3 Suppl):S2-S15. PMC: 3268359. DOI: 10.1016/j.pain.2010.09.030. View

Hao S, Wolfe D, Glorioso J, Mata M, Fink D . Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain. 2008; 13(4):380-6. PMC: 2656597. DOI: 10.1016/j.ejpain.2008.05.008. View

Kalso E, Edwards J, Moore A, McQuay H . Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112(3):372-380. DOI: 10.1016/j.pain.2004.09.019. View

10.

Chattopadhyay M, Goss J, Wolfe D, Goins W, Huang S, Glorioso J . Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain. 2004; 127(Pt 4):929-39. DOI: 10.1093/brain/awh103. View

11.

Wallace M, Yaksh T . Long-term spinal analgesic delivery: a review of the preclinical and clinical literature. Reg Anesth Pain Med. 2000; 25(2):117-57. DOI: 10.1053/rapm.2000.0250117. View

12.

BRAZ J, Beaufour C, Coutaux A, Epstein A, Cesselin F, Hamon M . Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001; 21(20):7881-8. PMC: 6763863. View

13.

Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D . Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7(10):859-66. DOI: 10.1038/sj.gt.3301184. View

14.

Milligan E, Sloane E, Langer S, Hughes T, Jekich B, Frank M . Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain. 2006; 126(1-3):294-308. DOI: 10.1016/j.pain.2006.07.009. View

15.

Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H . Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001; 19(9):2542-54. DOI: 10.1200/JCO.2001.19.9.2542. View

16.

Gavva N, Treanor J, Garami A, Fang L, Surapaneni S, Akrami A . Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain. 2008; 136(1-2):202-10. DOI: 10.1016/j.pain.2008.01.024. View

17.

Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T . Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol. 2004; 15(6):988-9. DOI: 10.1093/annonc/mdh225. View

18.

Finegold A, Mannes A, Iadarola M . A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther. 1999; 10(7):1251-7. DOI: 10.1089/10430349950018238. View

19.

Hao S, Mata M, Goins W, Glorioso J, Fink D . Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003; 102(1-2):135-42. DOI: 10.1016/s0304-3959(02)00346-9. View

20.

de Bruyn G, Vargas-Cortez M, Warren T, Tyring S, Fife K, Lalezari J . A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2005; 24(7):914-20. DOI: 10.1016/j.vaccine.2005.08.088. View